Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE18.5700
- TODAY'S CHANGE (%)-0.1000 (-0.5356%)
- Bid / Lots18.5500/ 1
- Ask / Lots19.6500/ 2
- Open / Previous Close18.7100 / 18.6700
- Day Range
- 52 Week Range
- Volume306,403
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 2910 | 18.71 |
| 09:39 ET | 100 | 18.68 |
| 09:41 ET | 189 | 18.76 |
| 09:48 ET | 1361 | 18.665 |
| 09:52 ET | 100 | 18.69 |
| 09:56 ET | 1198 | 18.66 |
| 09:57 ET | 200 | 18.6503 |
| 10:03 ET | 100 | 18.62 |
| 10:06 ET | 2517 | 18.5447 |
| 10:08 ET | 1545 | 18.48 |
| 10:10 ET | 300 | 18.46 |
| 10:12 ET | 1569 | 18.5 |
| 10:14 ET | 100 | 18.485 |
| 10:15 ET | 300 | 18.45 |
| 10:17 ET | 400 | 18.44 |
| 10:19 ET | 300 | 18.455 |
| 10:26 ET | 100 | 18.455 |
| 10:28 ET | 100 | 18.465 |
| 10:30 ET | 845 | 18.56 |
| 10:32 ET | 1561 | 18.56 |
| 10:33 ET | 11647 | 18.615 |
| 10:35 ET | 200 | 18.64 |
| 10:37 ET | 1300 | 18.61 |
| 10:42 ET | 1968 | 18.58 |
| 10:44 ET | 736 | 18.51 |
| 10:46 ET | 561 | 18.515 |
| 10:48 ET | 104 | 18.5 |
| 10:50 ET | 400 | 18.44 |
| 10:57 ET | 1447 | 18.395 |
| 11:00 ET | 200 | 18.33 |
| 11:02 ET | 1805 | 18.39 |
| 11:04 ET | 600 | 18.46 |
| 11:06 ET | 500 | 18.45 |
| 11:08 ET | 340 | 18.46 |
| 11:09 ET | 100 | 18.45 |
| 11:11 ET | 100 | 18.43 |
| 11:18 ET | 108 | 18.44 |
| 11:20 ET | 200 | 18.445 |
| 11:22 ET | 415 | 18.45 |
| 11:24 ET | 200 | 18.48 |
| 11:27 ET | 753 | 18.505 |
| 11:31 ET | 100 | 18.53 |
| 11:33 ET | 975 | 18.57 |
| 11:49 ET | 100 | 18.63 |
| 11:51 ET | 200 | 18.64 |
| 11:54 ET | 513 | 18.62 |
| 11:56 ET | 213 | 18.64 |
| 11:58 ET | 700 | 18.6 |
| 12:00 ET | 100 | 18.59 |
| 12:02 ET | 100 | 18.56 |
| 12:05 ET | 100 | 18.59 |
| 12:07 ET | 200 | 18.62 |
| 12:09 ET | 8000 | 18.58 |
| 12:12 ET | 700 | 18.58 |
| 12:14 ET | 504 | 18.61 |
| 12:16 ET | 500 | 18.59 |
| 12:20 ET | 100 | 18.58 |
| 12:21 ET | 300 | 18.6 |
| 12:30 ET | 700 | 18.58 |
| 12:38 ET | 612 | 18.55 |
| 12:39 ET | 300 | 18.55 |
| 12:43 ET | 375 | 18.5797 |
| 12:50 ET | 500 | 18.53 |
| 12:59 ET | 565 | 18.5 |
| 01:06 ET | 119 | 18.5214 |
| 01:08 ET | 100 | 18.525 |
| 01:14 ET | 362 | 18.535 |
| 01:24 ET | 798 | 18.54 |
| 01:26 ET | 403 | 18.55 |
| 01:33 ET | 104 | 18.56 |
| 01:42 ET | 700 | 18.55 |
| 01:44 ET | 100 | 18.54 |
| 01:46 ET | 500 | 18.54 |
| 01:48 ET | 300 | 18.54 |
| 02:00 ET | 600 | 18.515 |
| 02:09 ET | 1438 | 18.45 |
| 02:18 ET | 515 | 18.43 |
| 02:22 ET | 150 | 18.425 |
| 02:26 ET | 220 | 18.44 |
| 02:27 ET | 1163 | 18.46 |
| 02:31 ET | 600 | 18.43 |
| 02:33 ET | 100 | 18.42 |
| 02:36 ET | 887 | 18.41 |
| 02:40 ET | 100 | 18.44 |
| 02:44 ET | 500 | 18.41 |
| 02:49 ET | 600 | 18.39 |
| 02:51 ET | 200 | 18.4 |
| 02:54 ET | 1257 | 18.43 |
| 02:58 ET | 195 | 18.44 |
| 03:00 ET | 1650 | 18.43 |
| 03:02 ET | 800 | 18.47 |
| 03:03 ET | 100 | 18.485 |
| 03:05 ET | 100 | 18.485 |
| 03:12 ET | 1212 | 18.48 |
| 03:14 ET | 734 | 18.52 |
| 03:16 ET | 450 | 18.5 |
| 03:18 ET | 2642 | 18.5 |
| 03:20 ET | 700 | 18.53 |
| 03:23 ET | 985 | 18.515 |
| 03:25 ET | 1642 | 18.455 |
| 03:27 ET | 1132 | 18.47 |
| 03:30 ET | 1608 | 18.52 |
| 03:34 ET | 486 | 18.49 |
| 03:36 ET | 489 | 18.495 |
| 03:38 ET | 1522 | 18.515 |
| 03:39 ET | 500 | 18.51 |
| 03:43 ET | 4500 | 18.5 |
| 03:45 ET | 6854 | 18.485 |
| 03:48 ET | 1127 | 18.455 |
| 03:50 ET | 2423 | 18.44 |
| 03:52 ET | 1368 | 18.48 |
| 03:54 ET | 617 | 18.509 |
| 03:56 ET | 500 | 18.51 |
| 03:57 ET | 1976 | 18.505 |
| 03:59 ET | 98561 | 18.57 |
May 7, 2024
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference, from 4:01PM ET on Tuesday May 07, 2024 by Dow Jones
4:01PM ET on Tuesday May 07, 2024 by Dow Jones
May 3, 2024
DJ Kiniksa Pharmaceuticals Initiated at Overweight by Wells Fargo, from 11:59AM ET on Friday May 03, 2024 by Dow Jones
11:59AM ET on Friday May 03, 2024 by Dow Jones
May 1, 2024
DJ Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan, from 10:58AM ET on Wednesday May 01, 2024 by Dow Jones
10:58AM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.3B | 218.0x | --- |
Ginkgo Bioworks Holdings Inc | 1.2B | -1.3x | --- |
Dynavax Technologies Corp | 1.5B | 236.6x | --- |
BioCryst Pharmaceuticals Inc | 1.3B | -6.2x | --- |
Zai Lab Ltd | 1.8B | -5.2x | --- |
MannKind Corp | 1.2B | 192.1x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President, Chief Commercial Officer
- Ross Moat
- Senior Vice President, Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.32 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 218.0x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | 121.9x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
